Business Context and Reporting Period
This Form 8-K Current Report was filed by Alector, Inc. on December 11, 2019. The filing discloses the appointment of Shehnaaz Suliman, M.D., as the Company's President and Chief Operating Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
The primary material change is the addition of Dr. Suliman to the executive leadership team. She brings prior experience from Theravance Biopharma, Genentech, Roche, Gilead Sciences, and Lehman Brothers.
Compensation and Management Commentary
Dr. Suliman's compensation package, effective December 3, 2019, includes:
- Base Salary: $450,000 annually.
- Target Bonus: 45% of base salary ($202,500) for retention and performance.
- Equity: Stock option to purchase 550,000 shares of common stock, vesting over four years.
- Agreements: Standard Indemnification Agreement and Change in Control/Severance Agreement (Tier 2 level).
There are no family relationships or undisclosed transactions requiring disclosure under Regulation S-K.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 550,000 stock options in Exhibit 99.1 (Offer Letter).
- Review the specific terms of the Tier 2 Change in Control and Severance Agreement referenced from the Form S-1.
- Confirm the impact of this leadership change on the Company's strategic roadmap for neurodegenerative disease therapeutics.